NBIX vs ZVRA · P/E 45, rev $1.77B vs P/E 6.3, rev $75.9M
Neurocrine Biosciences Inc (NBIX) versus Zevra Therapeutics Inc. (ZVRA) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported ZVRA revenue for 2026-06-30 was $75.9M. Net income was $46.6M. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
Not investment advice. Open the NBIX and ZVRA stock pages for the full models.
Not investment advice.